Saturday 17 October 2026
Export TTRX’s income statement to Excel — free account
Turn Therapeutics Inc.
TTRX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 343.5% and free cash flow fell 74.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
10.57
1.02
−8.80%
Follow TTRX
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | — | 2.57 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | — | 26.50 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 2 | 2 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | — | — | — | — | — | (2) | (3) | |||||
| EBT margin, % | — | — | — | — | — | — | — | — | 0.00 | 0.00 | |||||
| Net income | — | — | — | — | — | — | — | — | (2) | (3) | |||||
| Depreciation | — | — | — | — | — | — | — | — | 0 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | — | — | — | — | (0.07) | (0.12) | |||||
| Cash flow | — | — | — | — | — | — | — | — | (0.05) | (0.09) | |||||
| Capex | — | — | — | — | — | — | — | — | 0.00 | (0.01) | |||||
| Free cash flow | — | — | — | — | — | — | — | — | (0.05) | (0.10) | |||||
| Book value | — | — | — | — | — | — | — | — | (0.01) | 0.17 | |||||
| Shares, m | — | — | — | — | — | — | — | — | 27 | 28 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | (1) | (3) | ||||
| Capex | — | — | — | — | — | — | — | — | 0 | 0 | |||||
| Free cash flow | — | — | — | — | — | — | — | — | (1) | (3) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 0 | (1) | ||||
| Total debt | — | — | — | — | — | — | — | — | — | — | |||||
| Net debt | — | — | — | — | — | — | — | — | (1) | (5) | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | 0 | 5 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | 0.00 | (44.95) | ||||
| ROIC | — | — | — | — | — | — | — | — | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | — | — | — | — | 0.00 | (141.67) | |||||
Negative figures in brackets.
Charts ten years each
Turn Therapeutics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| AVIR Atea Pharmaceuticals, Inc. | $363.3M | — (loss-making) | — (loss-making) | +295.16% (above 0%: growing) | n/m | +85.53% (above 0%: growing) | 0.00% | 0.00% | Compare |
| FENC Adherex Technologies Inc. | $362.9M | — (loss-making) | 31.4× | +85.18% (above 0%: growing) | n/m | +101.36% (above 0%: growing) | 95.97% | 9.72% | Compare |
| TTRX Turn Therapeutics Inc. | $345.3M | — (loss-making) | — | — | n/m | −74.76% (below 0%: shrinking) | — | 0.00% | |
| OBIO Orchestra BioMed Holdings, Inc. | $345.0M | — (loss-making) | — (loss-making) | −89.47% (below 0%: shrinking) | n/m | −25.87% (below 0%: shrinking) | 71.59% | (25,404.55%) | Compare |
| CCCC C4 Therapeutics, Inc. | $342.0M | — (loss-making) | — (loss-making) | +2.75% (above 0%: growing) | n/m | +86.84% (above 0%: growing) | 100.00% | (397.88%) | Compare |
| RLMD Relmada Therapeutics, Inc. | $341.3M | — (loss-making) | — | — | n/m | −50.06% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| IRD Opus Genetics, Inc. | $336.9M | — (loss-making) | — (loss-making) | −73.80% (below 0%: shrinking) | n/m | −16.37% (below 0%: shrinking) | 100.00% | (2,182.78%) | Compare |
| ENTA Enanta Pharmaceuticals, Inc. | $334.1M | — (loss-making) | — (loss-making) | −21.60% (below 0%: shrinking) | n/m | −157.51% (below 0%: shrinking) | 100.00% | (120.04%) | Compare |
| CYPH Cypherpunk Technologies Inc. | $325.5M | 4.4× | — (loss-making) | 0.00% | n/m | +15.53% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $341.7M | — | — | 0.00% | — | −0.42% | 83.78% | (60.02%) |
Turn Therapeutics Inc. (TTRX) key facts
- Concern: Turn Therapeutics Inc. reported a net loss of $3.2 million, or a loss of $0.12 per share, for fiscal 2025.
- Turn Therapeutics Inc. (TTRX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, TTRX traded at $10.57, a market capitalization of $345.3 million.
- Return on equity was −141.7% and debt-to-equity 8.83.